Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Teaming up to take down Duchenneon September 6, 2019 at 5:04 pm
For Nicola Worsfold and her husband Ed, the day they were told their six-year-old son Owen had Duchenne Muscular Dystrophy (DMD) is one they’ll never forget. “It was like someone took a huge ...
- NMD Summit 2019: Advancing Drug Development for Neuromuscular Diseaseson September 6, 2019 at 7:15 am
and Duchenne muscular dystrophy (DMD), among other rare diseases, to combat challenges in the industry. There are a number of different events taking place across the whole summit, including expert ...
- Capricor Therapeutics to Present at Upcoming Conferenceson September 6, 2019 at 5:30 am
06, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of ...
- PTC Therapeutics Celebrates the Fifth Anniversary of STRIVE Grant Awards by Announcing 2019 Award Winnerson September 6, 2019 at 5:00 am
6, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT, -0.55% is pleased to announce the recipients of the Company's 2019 global STRIVE Awards program, designed to support non-profit organizations ...
- Parent Project Muscular Dystrophy, I-ACT for Children, and Critical Path Institute Host Duchenne Muscular Dystrophy Platform Trial Community Meetingon September 5, 2019 at 7:37 am
HACKENSACK, N.J., Sept. 5, 2019 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced that ...
- Muscular Dystrophy Association Awards 25 Grants Totaling More Than $6.6 Million for Neuromuscular Disease Researchon September 5, 2019 at 6:00 am
5, 2019 /PRNewswire/ -- The Muscular Dystrophy Association (MDA ... lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT), congenital muscular dystrophy (CMD), Duchenne muscular dystrophy (DMD), ...
- Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2019-2023 | Patient Assistance Programs to Boost Growth | Technavioon September 4, 2019 at 4:37 am
The global Duchenne muscular dystrophy (DMD) therapeutics market size is poised to reach USD 2.23 billion by 2023, according to a new report by Technavio, progressing at a CAGR of 37% during the ...
- Eastpointe woman with muscular dystrophy needs home ramp before she can get power wheelchairon September 3, 2019 at 7:38 pm
Myers was born with Duchenne muscular dystrophy - a fatal muscle disease that overtime causes muscle degeneration. "I just get weaker, nothing they can do about it," she said. About a decade ago it ...
- CureDuchenne Inspires Duchenne Community to Raise Awareness and Funds for a Cure on World Duchenne Dayon September 3, 2019 at 10:22 am
CureDuchenne, the leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, is encouraging the Duchenne community to take action on this World Duchenne Day, ...
- Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients with Duchenne Muscular Dystrophyon August 27, 2019 at 7:18 am
Pratteln, Switzerland, August 27, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne muscular dystrophy ...
via Bing News